The mechanism of tumor cell clearance by rituximab in vivo in patients with B-cell chronic lymphocytic leukemia: Evidence of caspase activation and apoptosis induction

Blood

Volumn 99, Issue 3, 2002, Pages 1038-1043

  Byrd, John C ^a,b,c   Kitada, Shinichi ^a,b,c   Flinn, Ian W ^a,b,c   Aron, Jennifer L ^a,b,c   Pearson, Michael ^a,b,c   Lucas, David ^a,b,c   Reed, John C ^a,b,c  

^a OHIO STATE UNIVERSITY   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c BURNHAM INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; CASPASE; CASPASE 3; CASPASE 9; CASPASE INHIBITOR; CD20 ANTIGEN; COMPLEMENT; FLUDARABINE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN MCL 1; RITUXIMAB; UNCLASSIFIED DRUG; X LINKED INHIBITOR OF APOPTOSIS;

APOPTOSIS; ARTICLE; B CELL LEUKEMIA; CANCER CHEMOTHERAPY; CELL COUNT; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CLINICAL TRIAL; CYTOLYSIS; CYTOTOXICITY; DRUG MECHANISM; DRUG SENSITIVITY; ENZYME ACTIVATION; ENZYME DEGRADATION; HUMAN; HUMAN CELL; MULTICENTER STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TUMOR CELL;

EID: 0036464611     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.V99.3.1038     Document Type: Article

References (42)

1. Serotherapy of a patient with a monoclonal antibody directed against a human lymphoma-associated antigen
2. Novel therapies for chronic lymphocytic leukemia in the 21st century
3. Single agent monoclonal antibody efficacy in bulky non-Hodgkin's lymphoma: Results of a phase II trial of rituximab
4. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a four-dose treatment program
5. Results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma
6. IDEC-C2B8 (rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma
7. Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma
8. Rituximab dose-escalation trial in chronic lymphocytic leukemia
9. Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity
10. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20
11. Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets
12. Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies
13. National Cancer Institute-sponsored working group guidelines for chronic lymphocytic leukemia: Revised guidelines for diagnosis and treatment
14. Depsipeptide (FR901228): A novel therapeutic agent with selective, in vitro activity against human B-cell chronic lymphocytic leukemia cells
15. Detection of multiple antigens on Western blots
16. Immunohistochemical analysis of mcl-1 and bcl-2 proteins in normal and neoplastic lymph nodes
17. Reduced expression of pro-apoptotic gene Bax is associated with poor response rates to combination chemotherapy and shorter survival in women with metastatic breast adenocarcinoma
18. Immunolocalization of the ICE/Ced-3-family protease, CPP32 (caspase-3), in non-Hodgkin's lymphomas (NHLs), chronic lymphocytic leukemias (CLL), and reactive lymph nodes
19. Release of caspase-9 form mitochondria during neuronal apoptosis and cerebral ischemia
20. Human Daxx regulates Fas-induced apoptosis from nuclear PML oncogenic domains (PODs)
21. Dysregulation of apoptosis in cancer
22. bcl-2 gene hypomethylation and high-level expression in B-cell chronic lymphocytic leukemia
23. Elevated Bcl-2/Bax are a consistent feature of apoptosis resistance in B-cell chronic lymphocytic leukaemia and are correlated with in vivo chemoresistance
24. Drug-induced apoptosis in B-cell chronic lymphocytic leukemia: Relationship between p53 gene mutation and bcl-2/bax proteins in drug resistance
25. Regulation of clinical chemoresistance by bcl-2 and bax oncoproteins in B-cell chronic lymphocytic leukaemia
26. Expression of apoptosis-regulating proteins in chronic lymphocytic leukemia: Correlations with in vitro and in vivo chemoresponses
27. Bryostatin and CD40-ligand enhance apoptosis resistance and induce expression of cell survival genes in B-cell chronic lymphocytic leukaemia
28. In vitro evaluation of fludarabine in combination with cyclophosphamide and/or mitoxantrone in B-cell chronic lymphocytic leukemia
29. IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspases, and anticancer drugs
30. IAPs block apoptotic events induced by caspase-8 and cytochrome c by direct inhibition of distinct caspases
31. Chimeric anti-CD20 antibody (IDEC-C2B8) is apoptotic and sensitizes drug resistant human B-cell lymphomas and AIDS related lymphomas to the cytotoxic effect of CDDP, VP-16, and toxins
32. Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy
33. Rituximab adds to therapeutic efficacy of fludarabine in previous Untreated patients with CLL: Results from CALGB 9712
34. Signaling events involved in anti-CD20-induced apoptosis of malignant human B cells
35. Clustered CD20 induced apoptosis: src-family kinase, the proximal regulator of tyrosine phosphorylation, calcium influx, and caspase 3-dependent apoptosis
36. Intracellular pathways of CD20-induced apoptosis
37. Cytochrome c: Can't live with it - Can't live without it
38. Nucleotide requirements for the in vitro activation of the apoptosis protein-activating factor-1-mediated caspase pathway
39. Mitochondria and apoptosis
40. Involvement of Fas ligand and Fas-mediated pathway in the cytotoxicity of human natural killer cells
41. X-linked IAP is a direct inhibitor of cell-death proteases
42. Expression and prognostic significance of IAP-family genes in human cancers and myeloid leukemias